The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

High purity epoxide compounds, methods for preparing the high purity epoxide compounds, and compositions derived from the epoxide compounds are provided. Also provided are materials and articles derived from the epoxide compounds.

An oxygen absorbing agent containing a compound (A) of formula (I):

##STR00001##

wherein X is a chalcogen atom, R.sup.1 and R.sup.2 are each any one of an alkyl group which optionally has a substituent, an alkenyl group which optionally has a substituent, an aryl group which optionally has a substituent, and an aralkyl group which optionally has a substituent, R.sup.3 and R.sup.4 are each any one of a hydrogen atom, an alkyl group which optionally has a substituent, an alkenyl group which optionally has a substituent, an aryl group which optionally has a substituent, and an aralkyl group which optionally has a substituent, and R.sup.5 is a polymerizable group; and a transition metal salt (B).

An oxygen absorbing agent containing a compound (A) of formula (I):

##STR00001##

wherein X is a chalcogen atom, R.sup.1 and R.sup.2 are each any one of an alkyl group which optionally has a substituent, an alkenyl group which optionally has a substituent, an aryl group which optionally has a substituent, and an aralkyl group which optionally has a substituent, R.sup.3 and R.sup.4 are each any one of a hydrogen atom, an alkyl group which optionally has a substituent, an alkenyl group which optionally has a substituent, an aryl group which optionally has a substituent, and an aralkyl group which optionally has a substituent, and R.sup.5 is a polymerizable group; and a transition metal salt (B).

A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.

A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.